

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

June 19th, 2025

Company: Chordia Therapeutics, Inc
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: Head of Corporate Management Yoshihiko Satoh

Notice of Receipt of Grant

Kanagawa Japan

June 19th, 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; Chief Executive Officer: Hiroshi Miyake) (“Chordia”) announced that it has been selected to receive a grant for the fourth quarter of the fiscal year ending August 31, 2025 (June 1, 2025 - August 31, 2025).

1. Details of the grant income

Chordia today announced that it has entered into a subcontract research and development agreement with Kyoto University, a national university corporation, for the “Non-clinical study of novel therapeutic agents for refractory tumors with RNA splicing mutations” under the project of “Research Project for Innovative Cancer Therapy Application” (hereinafter referred to as the ‘Project’) of the Japan Agency for Medical Research and Development (hereinafter referred to as the “AMED”). Chordia will receive a grant of 30,000 thousand yen from the Project for the fiscal year ending March 2026.

2. Impact on Business Results

The impact of the above grant on our business results will be recorded as non-operating income after we receive the final notification from AMED, but will not affect our business forecast for the current fiscal year. Chordia will make another announcement when the timing of the posting of non-operating income is determined.

About Chordia Therapeutics

Chordia’s lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research of several preclinical assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please contact our website <https://www.chorditherapeutics.com/en/>.